Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2023-08-17 00:00:00 ET · period of report 2023-08-15 · accession 0001140361-23-040321 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-08-17 | 2023-08-15+ | ADMA | LENZ BRIAN | EVP, CFO | S - Sale+OE | $4.53 | -389.8K | 782.0K | -33% | -$1.77M |
| D | 2023-08-17 | 2023-08-15 | ADMA | LENZ BRIAN | EVP, CFO | F - Tax | $4.61 | -631.1K | 960.2K | -40% | -$2.91M |
| DM | 2023-08-17 | 2023-08-15 | ADMA | LENZ BRIAN | EVP, CFO | M - OptEx | $3.11 | +809.3K | 1.25M | +184% | +$2.51M |
| DM | 2023-08-17 | 2023-08-15 | ADMA | LENZ BRIAN | EVP, CFO | M - OptEx | $3.11 | -809.3K | 0 | -100% | -$2.51M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-08-15 | S | D | 211,578 | $4.60 | 782,013 | D | — | — | (F1) Reflects the weighted average price of sales on August 15, 2023. The shares were sold in multiple transactions at prices ranging from $4.60 to $4.65, inclusive. |
| 2 | Common | Common Stock | 2023-08-15 | F | D | 631,078 | $4.61 | 960,197 | D | — | — | |
| 3 | Common | Common Stock | 2023-08-15 | M | A | 192,472 | $3.66 | 1,591,275 | D | — | — | |
| 4 | Common | Common Stock | 2023-08-15 | M | A | 150,000 | $3.71 | 1,398,803 | D | — | — | |
| 5 | Common | Common Stock | 2023-08-16 | S | D | 178,184 | $4.45 | 782,013 | D | — | — | (F2) Reflects the weighted average price of sales on August 16, 2023. The shares were sold in multiple transactions at prices ranging from $4.40 to $4.535, inclusive. (F3) Includes (i) 135,175 RSUs granted on March 6, 2023 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (ii) 103,125 unvested RSUs granted on March 7, 2022 that will vest quarterly on the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 185,625 unvested Time-Based RSUs granted on September 29, 2021, subject to time based vesting conditions (the "Time-Based RSUs") which shall vest in eight (8) equal quarterly installments over a period of two years following December 31, 2022, becoming fully vested on December 31, 2024 and that will be settled into common stock upon vesting, subject to the reporting person's continued employment on the applicable vesting date; (F4) (continued from footnote 3) (iv) 30,480 unvested RSUs granted on February 25, 2021, of which 27,500 unvested RSUs will vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and 2,980 unvested RSUs are subject to cliff vesting with one-third of such RSUs vesting on each anniversary of the date of grant over three years, subject to the reporting person's continued service as of the applicable vesting date, and in each case will be settled into common stock upon vesting; (F5) (continued from footnote 4) (v) 10,000 unvested RSUs granted on February 28, 2020, which vest quarterly on each anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date and will be settled into common stock upon vesting; and (vi) 317,608 shares of common stock owned by the reporting person, which reflects prior purchases and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes. |
| 6 | Common | Common Stock | 2023-08-15 | M | A | 85,416 | $2.92 | 1,048,803 | D | — | — | |
| 7 | Common | Common Stock | 2023-08-15 | M | A | 83,979 | $2.35 | 963,387 | D | — | — | |
| 8 | Common | Common Stock | 2023-08-15 | M | A | 97,395 | $1.67 | 879,408 | D | — | — | |
| 9 | Common | Common Stock | 2023-08-15 | M | A | 200,000 | $3.22 | 1,248,803 | D | — | — | |
| 10 | Derivative | Stock Option (Right to Buy) | 2023-08-15 | M | D | 85,416 | $2.92 | 14,584 | D | $2.92 · — to 2030-02-28 | 85,416 Common Stock | (F8) The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 28, 2024. |
| 11 | Derivative | Stock Option (Right to Buy) | 2023-08-15 | M | D | 83,979 | $2.35 | 55,021 | D | $2.35 · — to 2031-02-25 | 83,979 Common Stock | (F7) The options vest over four years with 25% of the shares of Common Stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 25, 2025. |
| 12 | Derivative | Stock Option (Right to Buy) | 2023-08-15 | M | D | 97,395 | $1.67 | 177,605 | D | $1.67 · — to 2032-03-07 | 97,395 Common Stock | (F6) The options vest over four years with 25% of the shares of common stock underlying the options vesting on the one year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on March 7, 2026. |
| 13 | Derivative | Stock Option (Right to Buy) | 2023-08-15 | M | D | 200,000 | $3.22 | 0 | D | $3.22 · — to 2029-01-23 | 200,000 Common Stock | (F9) The option vests over a four-year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on February 23, 2020, becoming fully vested on January 23, 2023. |
| 14 | Derivative | Stock Option (Right to Buy) | 2023-08-15 | M | D | 150,000 | $3.71 | 0 | D | $3.71 · — to 2028-02-09 | 150,000 Common Stock | (F10) The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on March 9, 2019, becoming fully vested on February 9, 2022. |
| 15 | Derivative | Stock Option (Right to Buy) | 2023-08-15 | M | D | 192,472 | $3.66 | 0 | D | $3.66 · — to 2027-06-06 | 192,472 Common Stock | (F11) The option vests over a four year period with 25% of the shares of common stock underlying the option vesting on the one year anniversary of the grant date and the remaining 75% of the shares of common stock underlying the option vesting in equal monthly installments thereafter beginning on July 6, 2018, becoming fully vested on June 6, 2021. |